Evidence map›Paper›PMID 31168399›Full record

ArticleLupus science & medicine2019

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice.

William Stohl, Ning Yu, Samantha A Chalmers, Chaim Putterman, Chaim O Jacob

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

William StohlDivision of Rheumatology, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-8272-7873
Ning YuDivision of Rheumatology, University of Southern California, Los Angeles, California, USA.
Samantha A ChalmersDivision of Rheumatology, Albert Einstein College of Medicine, Bronx, New York, USA.
Chaim PuttermanDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Chaim O JacobDivision of Rheumatology, University of Southern California, Los Angeles, California, USA.
University of Southern California · USAlbert Einstein College of Medicine · US

Funding

Leukocyte NADPH Oxidase Variants in LupusR01AR072212 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JACOB, CHAIM O. · 2017 to 2022
$2.8M
NIAMS NIH HHS R01 AR072212
6 · The paper itself

Abstract

BACKGROUND/

objectiveTreatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To begin to address this, we generated SLE-prone NZM 2328 mice with lifelong reduction in CTLA-4 expression.

methodsSince CTLA-4-deficient (

resultsCTLA-4 expression was lower in NZM.

conclusionLifelong reduction in CTLA-4 expression in NZM mice neither accelerated nor aggravated SLE. Expansion in Treg cells may have played a protective role. Our observations raise the hope that long-term treatment of patients with SLE with an anti-CTLA-4 agent, should the need arise, would not adversely affect SLE disease activity.

Indexed as

animal modelcheckpoint proteinCTLA-4lupus

Identifiers

PMID31168399
PMCPMC6519407
OpenAlexW2916051956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.